NCT02897063
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 13 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: enrollment goal was not met. Show 4 more changesShow less
- Eligibility criteria expanded, about 13 words
- Study completion date changed from estimate of Dec 2026 to Oct 2026
- Study description revised
- Site details revised
- Notable Primary completion date: Sep 2025 to Sep 2026
- Study completion date: Dec 2025 to Dec 2026
- Site contact updated
- Notable Primary completion date: Sep 2024 to Sep 2025
- Study completion date: Dec 2024 to Dec 2025
- Site contact updated
- Minor Primary completion date: Mar 2024 to Sep 2024
- Study completion date: Aug 2024 to Dec 2024
- Notable Primary completion date: Mar 2023 to Mar 2024
- Study completion date: Aug 2023 to Aug 2024
Show 7 earlier versionsHide 7 earlier versions
- Minor Site contact updatedv11
- Notable Primary completion date: Mar 2021 to Mar 2023
- Study completion date: Aug 2021 to Aug 2023
- Notable Trial status: Suspended to Recruiting
- Site details revised
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Recruitment is temporarily suspended due to COVID-19 outbreak
- Site details revised
- Minor Site contact updatedv6
- Notable Phase: Not applicable to Phase 1
- Lead sponsor: Vanderbilt University to Vanderbilt University Medical Center
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Eligibility criteria expanded, about 2 words
- Start date: Aug 2016 to Sep 2016
- Site details revised
- Study description expanded, about 1 word
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of either droxidopa 300 mg or placebo after the first tilt table test, followed two hours later by a single oral dose of placebo.
Patients will be studied on two separate days, two days apart: one day with the active drug and one day with placebo. The order of the study days will be randomized. On each study day, patients will receive a single oral dose of placebo after the first tilt table test, followed two hours later by a single oral dose of either midodrine 10 mg or placebo.
Drugs: Droxidopa, Midodrine, Placebo
Sites
1 site in 1 country
- Autonomic Dysfunction Center/ Vanderbilt University Medical CenterNashville, Tennessee, United States